IR@PKUHSC  > 北京大学第二临床医学院  > 心血管内科
学科主题临床医学
Lipid-lowering efficacy and safety of varying doses of Simvastatin in patients with early stage acute coronary syndromes: one-year follow-up study
Zou, YC; Hu, DY; Yang, XC; Xu, ZM; Cui, LA; Liu, XH; Wei, Y; Gao, MM
关键词Simvastatin Acute Coronary Artery Syndromes Safty
刊名CHINESE MEDICAL JOURNAL
2003-06-01
116期:6页:853-856
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]HEART-DISEASE ; MYOCARDIAL-INFARCTION ; CHOLESTEROL LEVELS ; CLINICAL EVENTS ; PRAVASTATIN ; REDUCTION ; HYPERCHOLESTEROLEMIA ; ATHEROSCLEROSIS ; PREVENTION ; THERAPY
英文摘要

Objective To investigate whether patients, who are at risk of major acute coronary events, are safe to undergo and benefit from early intervention after using simvastatin.

Methods The study, was a randomized, open, two-dosage-control led trial to evaluate the safety and benefits of simvastatin administered to 197 patients (10 mg group, n = 98 and 20 mg group, n = 99), within 48 hours of hospitalization for a diagnosis of unstable angina or acute myocardial infarction (MI), with total cholesterol (TC) greater than or equal to180 mg/dL or low-density lipoprotein cholesterol (LDL-C) greater than or equal to100 mg/dL. Lipid levels were measured immediately, followed by the 3rd, 6th and 12th month after admission and all adverse events were recorded during follow-up.

Results TC levels fell by 10.15% and 14.52% in the 10 mg and 20 mg groups ( P < 0.05), and LDL-C levels fell 13.87% and 19.38% in the 10 mg and 20 mg groups, respectively ( P < 0.01), 12 months after using simvastatin. The rates of achieving target TC reached 26.3% and 36.5% in the 10 mg and 20 mg groups (P < 0.01), and that of LDL-C reached 28.2% and 40.3% in the 10 mg and 20 mg groups, respectively ( P < 0.01). There were higher rates of MI and re-hospitalization resulting from angina pectoris and revascularization in the 10 mg group compared with the 20 mg group.

Conclusions The results suggest that early intervention with the HMG-CoA reductase inhibitor, simvastatin, in acute coronary syndromes is possible and safe. It also indicates that the clinical dosage of simvastatin are relatively smaller than that for satisfactory lipid control in patients with acute coronary syndromes.

语种英语
WOS记录号WOS:000184024900013
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/53859
专题北京大学第二临床医学院_心血管内科
作者单位1.Capital Univ Med Sci, Chaoyang Hosp, Ctr Heart, Beijing 100020, Peoples R China
2.Peking Univ, Renmin Hosp, Dept Cardiol, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Zou, YC,Hu, DY,Yang, XC,et al. Lipid-lowering efficacy and safety of varying doses of Simvastatin in patients with early stage acute coronary syndromes: one-year follow-up study[J]. CHINESE MEDICAL JOURNAL,2003,116(6):853-856.
APA Zou, YC.,Hu, DY.,Yang, XC.,Xu, ZM.,Cui, LA.,...&Gao, MM.(2003).Lipid-lowering efficacy and safety of varying doses of Simvastatin in patients with early stage acute coronary syndromes: one-year follow-up study.CHINESE MEDICAL JOURNAL,116(6),853-856.
MLA Zou, YC,et al."Lipid-lowering efficacy and safety of varying doses of Simvastatin in patients with early stage acute coronary syndromes: one-year follow-up study".CHINESE MEDICAL JOURNAL 116.6(2003):853-856.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zou, YC]的文章
[Hu, DY]的文章
[Yang, XC]的文章
百度学术
百度学术中相似的文章
[Zou, YC]的文章
[Hu, DY]的文章
[Yang, XC]的文章
必应学术
必应学术中相似的文章
[Zou, YC]的文章
[Hu, DY]的文章
[Yang, XC]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。